VBI VACCINES INC. (TSE:VBV) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

VBI VACCINES INC. (TSE:VBV) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officer.

Story continues below

On March 29, 2019, Scott Requadt tendered his resignation from the Board of Directors, and all Board committees, of VBI Vaccines Inc. (the “Company”), effective March 31, 2019. The resignation of Mr. Requadt was not in connection with any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

About VBI VACCINES INC. (TSE:VBV)

VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).

An ad to help with our costs